Pharmaceuticals

Praluent Market 2026–2030: Forecast, Innovation, and Competitive Trends

March 6, 2026March 8, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the praluent market from 2026–2035 with trusted insights from The Business Research Company

What growth pattern is forecast for the Praluent Market size between 2026 and 2035?

Historically, the observed growth was due to an escalating prevalence of hypercholesterolemia, the inherent limitations of therapies relying solely on statins, enhanced cardiovascular risk screening efforts, the broadening availability of biologic cardiovascular drugs, and an increase in specialized cardiology care.

The projected growth during the forecast period can be attributed to an increased focus on aggressive lipid-lowering strategies, rising adoption in secondary prevention, the expansion of value-based cardiovascular care, growing payer support for pcsk9 inhibitors, and a heightened awareness of cardiovascular risk reduction.

Major trends anticipated in the forecast period include the increasing use of pcsk9 inhibitors in lipid management, rising adoption among high-risk cardiovascular patients, growing integration with statin combination therapy, the expansion of preventive cardiology programs, and an enhanced focus on long-term ldl control.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20261&type=smp

Which Drivers Are Impacting Market Performance In The Praluent Market?

The Praluent market is anticipated to grow due to the increasing prevalence of obesity. Obesity is defined as a medical state where excessive body fat accumulates, posing health risks, typically identified by a Body Mass Index (BMI) of 30 or greater. The increasing incidence of obesity stems primarily from changes in global dietary patterns and eating behaviors, marked by greater intake of ultra-processed foods, inactive lifestyles, and economic factors that make less healthy food options more accessible. Praluent aids in managing obesity by lowering LDL cholesterol levels in individuals suffering from obesity-related dyslipidemia; as a PCSK9 inhibitor, it boosts the liver’s capacity to clear LDL cholesterol from the bloodstream, thereby enhancing cardiovascular wellness and mitigating complications linked to obesity. For example, in May 2024, a report from the Office for Health Improvement and Disparities, a UK government body focused on public health, indicated that an estimated 64.0% of adults (18+) in England were either overweight or living with obesity between 2022 and 2023, with 26.2% specifically estimated to be living with obesity (BMI = 30 kg/m²). Consequently, the upward trend in obesity will propel the Praluent market’s expansion. The Praluent market is set for expansion driven by the growing integration of personalized medicine. Personalized medicine is an approach to treatment where medical professionals customize therapies based on a patient’s unique biological traits to enhance treatment efficacy. The increasing uptake of personalized medicine is due to a rising preference among clinicians for treatments that precisely match genetic and biomarker profiles, leading to more accurate therapeutic outcomes. Praluent facilitates the expanded use of personalized medicine as its specific PCSK9-inhibiting action enables clinicians to customize reductions in LDL-cholesterol according to each patient’s cardiovascular risk profile. As an illustration, in February 2025, BioSpace, Inc., a U.S. life science news platform, reported that in 2023, the FDA had approved 16 novel personalized treatments for patients with rare diseases, an increase from six approvals in 2022. Consequently, the rising adoption of personalized medicine is projected to propel the Praluent market forward.

Which Segments Are Contributing To The Growth Of The Praluent Market?

The praluent market covered in this report is segmented –

1) By Indication: Primary Hypercholesterolemia, Mixed Dyslipidemia, Established Atherosclerotic Cardiovascular Disease (ASCVD)

2) By Distribution Channel: Hospitals And Clinics, Retail Pharmacies, Specialty Pharmacies

3) By End-User: Ambulatory Care, Home Care

Which Competitive Trends Are Impacting The Structure Of The Praluent Market?

Leading companies in the praluent market are concentrating on developing innovative solutions, such as low-density lipoprotein cholesterol (LDL-C) lowering therapies, to address the increasing demand for advanced cardiovascular risk-reduction treatments. These LDL-C–lowering therapies are specialized medical interventions designed to significantly reduce levels of “bad cholesterol,” providing more precise, targeted, and sustained lipid control compared to traditional statins or lifestyle modifications alone. For instance, in March 2024, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, obtained extended approval from the U.S. Food and Drug Administration (FDA) for Praluent (alirocumab) injection, which is an advanced LDL-C–lowering biologic therapy. This updated approval permits its use as an add-on to diet and existing lipid-lowering treatments for pediatric patients aged 8 years and older who have heterozygous familial hypercholesterolemia (HeFH). Praluent functions as a PCSK9 inhibitor monoclonal antibody, designed to enhance LDL receptor availability, leading to a marked and sustained reduction in LDL-C. The therapy offers strong efficacy, a favorable safety profile, and less frequent dosing when compared to many conventional lipid-lowering options. By expanding access to children with genetic high cholesterol, the product helps in addressing early-onset cardiovascular risk and supports long-term heart health management.

Who Are The Top-Performing Companies In The Praluent Market In Recent Years?

Major companies operating in the praluent market are Sanofi S.A., Regeneron Pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/praluent-global-market-report

Which Region Currently Holds The Largest Share Of The Praluent Market?

North America was the largest region in the praluent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the praluent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Praluent Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20261&type=smp

Browse Through More Reports Similar to the Global Praluent Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Trade Finance Market Report 2026

https://www.thebusinessresearchcompany.com/report/trade-finance-global-market-report

Market Research Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795